Research programme: antibacterials - Arpida

Drug Profile

Research programme: antibacterials - Arpida

Alternative Names: Clostridium difficile infection therapies - Arpida; AR 2474; High affinity ligands for bacterial infections - Arpida; MRSA skin infection therapies - Arpida; Topical antibacterials - Arpida

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arpida
  • Developer Evolva Holding SA
  • Class Carbanilides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Clostridium infections; Skin and soft tissue infections

Most Recent Events

  • 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA
  • 25 Feb 2009 Suspended - Preclinical for Bacterial infections in European Union (Topical)
  • 25 Feb 2009 Suspended - Preclinical for Clostridium infections in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top